Neogenomics Inc. (NEO) stock forecast and price target
Price $16.02 · data as of November 13, 2026
12-month price target
Gold marker: average target · white marker: today’s price ($16.02)
Analyst ratings
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $0.20 | +70.0% | $808M |
| Next fiscal year ends December 31, 2027 | $0.31 | +54.2% | $887M |
| Next quarter ends December 31, 2026 | $0.06 | +7.6% | $211M |
| Quarter after ends March 31, 2027 | $0.05 | +440.0% | $206M |
Consensus of the analysts covering Neogenomics, updated daily. In the last 30 days 9 estimates were raised and 0 lowered.
Our model vs. Wall Street
Analysts see 46.1% upside over 12 months. Our discounted cash flow model with moderate assumptions puts Neogenomics’s intrinsic value about 84% below today’s market value, and it scores 0.8 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.
Frequently asked questions
What is the Neogenomics stock price target?
The average 12-month target from 10 analysts is $23.40, 46.1% above the current price of $16.02 Targets range from $19.00 to $35.00.
Is Neogenomics a buy according to analysts?
The consensus rating is “None” (2 strong buy, 6 buy, 3 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is Neogenomics expected to earn?
Analysts expect EPS of $0.20 for the fiscal year ending December 31, 2026 and $0.31 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.